Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.

Name: Verified Rigor Record — Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.
Item: Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.
Rating: 88
Author: Αlpha¹

Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA

Paper source

Open DOI

Αlpha¹ Rigor Review

Rigor Review Verified

Critical

High-priority

Action items to resolve · Critical / High

Confidence: highEngine: 7.6.0Source: full text

This Alpha1 Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a methodologically rigorous phase 3 RCT with strong scientific premise, clear design, adequate statistical analysis, and transparent reporting of limitations and funding. The main weaknesses are missing elements in demographic reporting (race/ethnicity, weight) and drug manufacturer details, and the absence of a data availability statement, which are all fixable reporting gaps.

All eight dimensions were applicable and evaluated. The reviewers largely converged; minor divergence on data code availability (warn vs fail) and key resources (pass vs warn) was resolved by weighing the specific evidence for missing items. The statistical verification component covered only 5 tests with consistent results — all unrecomputed statistics are unverified. No retracted or unresolved references were found.

10 major claims checked against the paper's own evidence: all adequately supported.

partialDiscussion, final paragraphReviewer 2
These findings support universal MMR testing in all patients with newly diagnosed colon cancer.
The study demonstrates benefit specifically in dMMR patients, which logically supports universal testing, but the paper does not directly provide evidence on testing implementation or cost-effectiveness.
Evidence: The study's focus on dMMR selection and the recommendation in the Discussion.
“These findings support universal MMR testing in all patients with newly diagnosed colon cancer, both to identify the Lynch syndrome and to determine eligibility for immunotherapy.”
partialResults, PatientsReviewer 3
Baseline demographic and clinical features were also similar to those of a large NCDB cohort of patients with dMMR stage III colon cancer, further reinforcing the representativeness of the study population.
The paper states similarity to NCDB cohort but provides no statistical comparison; the claim is based on a qualitative comparison, not a formal test.
Evidence: The demographics of our study population are similar to those reported for stage III dMMR colon cancers identified from the National Cancer Database.
“The demographics of our study population are similar to those reported for stage III dMMR colon cancers identified from the National Cancer Database.”
partialDiscussion, last paragraphReviewer 3
These findings support universal MMR testing in all patients with newly diagnosed colon cancer, both to identify the Lynch syndrome and to determine eligibility for immunotherapy.
The study shows benefit of immunotherapy in dMMR patients, supporting the rationale for testing, but the claim is an inference from the data rather than a direct result.
Evidence: The ATOMIC results have been incorporated into the most recent NCCN guidelines, which also extend these findings to T4bN0 stage II cancers.
“These findings support universal MMR testing in all patients with newly diagnosed colon cancer, both to identify the Lynch syndrome and to determine eligibility for immunotherapy.”
supportedAbstract, ResultsReviewers 1, 2, 3
The addition of atezolizumab to mFOLFOX6 significantly improved disease-free survival in stage III dMMR colon cancer.
The primary endpoint is met with a highly significant HR of 0.50 (95% CI 0.35-0.73, p<0.0001) from a well-conducted phase 3 trial.
Evidence: Reported 3-year DFS 86.3% vs 76.2%, HR 0.50, p<0.0001, from stratified log-rank test.
“The addition of atezolizumab to mFOLFOX6 significantly improved disease-free survival in stage III dMMR colon cancer.”
supportedDiscussion, last paragraphReviewer 1
The ATOMIC trial provides support for universal MMR testing in newly diagnosed colon cancer.
This is a logical implication of the trial results, not a direct finding, but it is a reasonable recommendation supported by the need to identify dMMR status for this therapy.
Evidence: Discussion states 'These findings support universal MMR testing in all patients with newly diagnosed colon cancer'.
“These findings support universal MMR testing in all patients with newly diagnosed colon cancer, both to identify the Lynch syndrome and to determine eligibility for immunotherapy.”
supportedResults, Overall SurvivalReviewer 1
No overall survival difference was observed at the first analysis.
Reported OS data show no significant difference (HR 0.90, p=0.68), with limited events. The claim is directly supported by the data presented.
Evidence: Reported 5-year OS 89.7% vs 87.9%, HR 0.90 (0.55-1.47), p=0.6787.
“Overall survival showed no statistically significant difference by study arm (stratified log-rank p value of 0.6787).”
supportedResults, Efficacy paragraphReviewer 2
No statistically significant difference in overall survival was observed between study arms.
Presented OS data show HR 0.90 (95% CI 0.55-1.47) with stratified log-rank p=0.6787, supporting the claim of no significant difference.
Evidence: Results report 31 vs 33 deaths, 5-year OS rates 89.7% vs 87.9%, stratified HR 0.90 (0.55-1.47), p=0.6787.
“Overall survival showed no statistically significant difference by study arm (stratified log-rank p value of 0.6787).”
supportedDiscussion, first paragraph and ConclusionReviewer 2
The addition of atezolizumab to mFOLFOX6 is an effective adjuvant treatment for resected stage III dMMR colon cancer.
The primary endpoint and the magnitude of benefit support this conclusion; caveats about immature OS and potential resistance are acknowledged.
Evidence: Primary DFS result (HR 0.50), subgroup analyses, and safety profile support effectiveness.
“In conclusion, the addition of atezolizumab to mFOLFOX6 resulted in a significant reduction in recurrence or death indicating it is an effective adjuvant treatment of patients with resected dMMR stage III colon cancer.”
supportedResults, EfficacyReviewer 3
No difference in overall survival has been observed between the study arms.
The OS analysis shows no statistically significant difference (HR 0.90, p=0.6787), supporting the claim.
Evidence: HR 0.90, 95% CI 0.55-1.47, stratified log-rank p=0.6787
“Overall survival showed no statistically significant difference by study arm (stratified log-rank p value of 0.6787). The 5-year overall survival rate was 89.7% (95% CI, 85.2 to 92.9) for atezolizumab plus mFOLFOX6 versus 87.9% (95% CI, 83.1 to 91.4) for mFOLFOX6 alone (stratified HR, 0.90; 95% CI, 0.55 to 1.47).”
supportedDiscussion, paragraph 1Reviewer 3
The addition of atezolizumab to mFOLFOX6 was associated with a ten percentage point absolute reduction and a 50% reduction in the hazard of disease recurrence or death.
The absolute difference in 3-year DFS is 86.3% - 76.2% = 10.1 percentage points, and the HR is 0.50, consistent with the claim.
Evidence: 3-year DFS 86.3% vs 76.2%, HR 0.50
“The addition of atezolizumab to mFOLFOX6 was associated with a ten percentage point absolute reduction and a 50% reduction in the hazard of disease recurrence or death compared to mFOLFOX6 alone.”

Recomputed 5 tests: 5 consistent, 0 inconsistent, 5 via agent-written checks.

Rigor

Eight Dimensions5 pass · 3 warn

10 major claims3 partial7 supported

6 copyedit issues flagged: mostly consistency, clarity, punctuation.

Checked 24 references: 24 verified.

Reproducibility

3 data/code links checked; 1 live.

datahttps://clinicaltrials.gov/ct2/show/NCT02912559LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://NEJM.orgUNVERIFIEDHTTP 403
Liveness indeterminate — content not checked.
datahttps://acknowledgments.alliancefound.orgUNVERIFIEDHTTP 403
Liveness indeterminate — content not checked.

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Alpha¹ Rigor Action ItemsFinal pass before journal submission

The paper is ready to submit after minor edits. The three 'warn' dimensions (biological_variables, key_resources, data_code_availability) require specific additions before submission, but none threaten the validity of the results. The copyedit issues are minor and easily addressed. Addressing the pre-submission action items below will bring the paper to a standard suitable for a high-impact journal.

1.
HIGHdata code
Add a formal data availability statement in the Methods or a dedicated Data Sharing section specifying how to access de-identified individual patient data (e.g., via the Alliance for Clinical Trials in Oncology data-sharing portal or a managed-access repository).
There is no data availability statement in the manuscript; NEJM and most journals require one for clinical trials to ensure reproducibility.
2.
HIGHreporting
Report race and ethnicity of participants in Table 1 to fully characterize the study demographics and comply with NIH policy.
Race/ethnicity are standard demographic variables for assessing generalizability; their absence is a notable gap in Table 1.
3.
HIGHreporting
Report body weight or note that weight was not collected in Table 1, as it is relevant for BSA-based drug dosing (FOLFOX).
Weight is an important health status variable for a trial involving weight-based chemotherapy dosing.
4.
HIGHrigor
Include the manufacturer/source for atezolizumab and each mFOLFOX6 component (e.g., Genentech for atezolizumab, standard suppliers for fluorouracil, oxaliplatin, leucovorin) in the Methods section.
Reagent identification requires source for reproducibility; the current Methods list doses but not vendors.
5.
HIGHreporting
Explicitly state that the trial is open-label and provide a brief rationale for the lack of blinding (e.g., due to differing infusion schedules and the impracticality of placebo infusions).
Blinding status is a standard reporting item; omitting it entirely could raise reviewer questions.
6.
HIGHreporting
Explicitly reference adherence to CONSORT reporting guidelines (e.g., 'This study is reported in accordance with the CONSORT 2010 statement') in the Methods.
CONSORT is the standard guideline for RCTs; referencing it signals commitment to transparent reporting.
7.
MEDIUMreporting
Harmonize the p-value for the primary endpoint between the Abstract (P<0.0001) and the Results text (p=0.0002) so they are consistent.
Copyedit flagged this inconsistency; p-values must be identical in abstract and main text to avoid confusion.
8.
MEDIUMdata code
Consider depositing the SAS analysis code in a public repository (e.g., GitHub, Zenodo) or state where it can be accessed upon request.
Code sharing enhances reproducibility; for an NCI-funded trial, this is an emerging expectation.
9.
MEDIUMreporting
Include a brief statement on verification of proportional hazards assumptions for the Cox model, or note that it was assessed and satisfied.
This is a standard model assumption; its verification adds methodological rigor despite being commonly omitted.
10.
MEDIUMreporting
Provide a timeline or planned publication venue for the deferred secondary endpoints (PRO-CTCAE, quality of life) to fully report all pre-specified outcomes.
Deferring outcomes is acceptable but should be transparently linked to a future report to avoid concerns about selective reporting.
11.
LOWcopyedit
Remove the extraneous metadata header numbers from the Abstract (line beginning with '319 nihpa') before submission.
This appears to be a PMC metadata artifact and should be cleaned to present a clean manuscript.
12.
LOWcopyedit
Clarify the statement about NCCN guidelines in Discussion paragraph 3 by specifying whether the extension to T4bN0 stage II is a direct recommendation or a statement of applicability.
The current phrasing is slightly ambiguous; clarifying avoids potential misinterpretation.

Full text (31,727 chars)Analyzed: Jul 6, 2026

Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →